Core Viewpoint - The announcement by Zhonghong Medical on November 4 indicates that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), has participated in bidding for centralized procurement projects in multiple cities and provinces, with potential selection of several products [1] Group 1: Procurement Projects - Kelong Medical is involved in bidding for centralized procurement projects in Putian City, Fuzhou City, Beijing, and Qujing City [1] - The products targeted for selection include disposable vacuum blood collection tubes, disposable nebulizers, and disposable intravenous indwelling needles [1] Group 2: Market Impact - If selected, the medical institutions in the procurement regions will prioritize the use of Kelong Medical's products during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The subsequent signing of sales contracts and implementation will help expand the market sales of the selected products, increase market share, and enhance brand influence, positively impacting the company's long-term development [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-099 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期分别参加了福建省莆田 市"Y 接头、真空采血管全省性联盟集中带量采购项目"、福建省福州市"一次 性使用温度传感器、雾化器全省性联盟集中带量采购项目"、北京市"静脉留置 针类及输液器类医用耗材集中带量采购项目"、云南省曲靖市"第七批医用耗材 （全省联盟）扩围带量采购项目"的投标工作。分别根据福建省莆田市"Y 接头、 真空采血管全省性联盟集中带量采购公告（第 7 号）"、福建省福州市"雾化器 全省性联盟集中带量采购公告（第 9 号）"、北京市"静脉留置针类、输液器类 医用耗材集中带量采购中选结果及委托配送企业的通知"、云南省曲靖市"第七 批医用耗材（全省联盟）扩围带量采购中选公告"显示，科伦医械部分产品拟中 选上述集中带量采购项目。现将相关情况公告如下： 品种分类 型号规格 中标产品及 注册证号 注册分类 适用范围 拟中选价 格及数量 拟供应 地区 一次 ...

Core Insights - The article reports on recent shareholding changes among executives at Zhonghong Medical, highlighting a significant increase in shares by General Manager Yang Hao despite a decline in the company's stock price [1][2]. Executive Shareholding Changes - On October 30, 2025, Yang Hao purchased 25,000 shares, representing 0.0058% of the total share capital, at an average price of 12.93 yuan per share, while the stock price fell by 2.07% to close at 12.78 yuan [1]. - In the past six months, Yang Hao has made several transactions, including a purchase of 5,000 shares on September 25 at 13.31 yuan and another purchase of 20,000 shares on September 22 at 13.55 yuan [1]. Current Executive Shareholding Status - The current shareholding status of executives shows that: - Chairman and legal representative Sang Shujun holds 47.77 million shares. - Yang Hao, the General Manager, now holds 50,000 shares after the recent purchase [2]. - Other executives, including Vice General Managers and non-independent directors, have not reported any shareholdings or recent changes [2]. Financing and Margin Trading Data - Recent financing data indicates a net inflow of 4.4264 million yuan in the last five days, with an increase in financing balance, while there was no net inflow in margin trading [2]. Institutional Ratings - There have been no institutional ratings for the stock in the last 90 days [3].

Core Points - The company Zhonghong Medical announced the completion of its share buyback plan as of the announcement date [1] - The total shares purchased by the company's general manager, Ms. Yang Hao, amounted to 50,000 shares, representing 0.0117% of the company's shares excluding those in the repurchase account [1] - The total amount spent on the share purchase was RMB 661,264.48, excluding transaction fees [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) has completed its share buyback plan, reaching the lower limit of the intended increase in shareholding [1] Summary by Categories Shareholding Increase - Ms. Yang Hao has cumulatively increased her shareholding by 50,000 shares through the Shenzhen Stock Exchange's centralized bidding system, which accounts for 0.0117% of the company's shares excluding those in the repurchase account [1] - The total amount spent on the increased shares is RMB 661,264.48 (excluding transaction fees) [1]

Company Summary - Zhonghong Medical (SZ 300981) announced on October 31 that its share buyback plan has reached the lower limit of the intended increase, and the plan has been completed [1] - Ms. Yang Hao has cumulatively increased her shareholding by 50,000 shares through the Shenzhen Stock Exchange, accounting for 0.0117% of the company's shares excluding those in the repurchase account, with an investment amount of approximately 660,000 RMB [1] - As of the report date, Zhonghong Medical's market capitalization stands at 5.6 billion RMB [1] Industry Summary - For the first half of 2025, Zhonghong Medical's revenue composition is entirely from the medical device industry, with a 100% share [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-098 中红普林医疗用品股份有限公司 关于公司高级管理人员增持股份计划实施完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、增持计划基本情况：中红普林医疗用品股份有限公司（以下简称"公司"） 总经理杨浩女士基于对公司未来发展的信心以及对公司长期投资价值的认可，自 2025 年 8 月 28 日起至 2026 年 2 月 27 日止，按照相关法律法规的规定增持公司 股份，以自有资金计划增持股份数量不低于 5 万股。 2、增持计划实施情况：截至本公告日，本次增持达到增持计划下限，增持 计划已实施完毕。杨浩女士通过深圳证券交易所系统集中竞价方式累计增持公司 股份 50,000 股，占公司剔除公司回购专用账户中的股份数量的 0.0117%，增持 股份金额为人民币 661,264.48 元（不含交易费用）。 公司于 2025 年 10 月 31 日收到公司总经理杨浩女士出具的《关于增持计划 实施完成的告知函》，现将情况公告如下： 一、增持计划的基本情况 1、增持主体：公司总经理杨浩 ...

Group 1 - The core point of the article highlights that Zhonghong Medical (SZ 300981) announced the convening of its 13th meeting of the fourth board of directors on October 28, 2025, via telecommunication, where it reviewed proposals including the revision of relevant systems [1] - For the first half of 2025, Zhonghong Medical's revenue composition is entirely from the medical device industry, accounting for 100.0% [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

Core Viewpoint - The company announced the approval of an asset impairment provision totaling 27.61 million yuan for the first three quarters of 2025 during its board meeting on October 28, 2025 [1] Summary by Category - **Company Announcement** - The company will hold its fourth board meeting on October 28, 2025, to review the asset impairment provision [1] - The total amount of asset impairment provision for the first three quarters of 2025 is 27.61 million yuan [1]

中红普林医疗用品股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为进一步提高公司的规范运作水平，加大对年报信息披露责任人的问 责力度，提高年报信息披露的质量和透明度，增强信息披露的真实性、准确性、完 整性和及时性，根据《中华人民共和国证券法》《中华人民共和国会计法》《上市公 司信息披露管理办法》《深圳证券交易所创业板股票上市规则》等法律法规、规范性 文件以及公司章程的规定，结合公司实际情况，制定本制度。 第二条 本制度是针对在年报信息披露工作中，公司有关人员不履行或者不正 确履行职责、义务或者其他个人原因致使公司年报披露发生重大差错，而追究相关 责任人责任的制度。 第三条 本制度适用于公司董事、高级管理人员、各子公司负责人、控股股东 及实际控制人，以及与年报信息披露工作有关的其他人员。 第四条 公司董事会办公室在董事会秘书的领导下负责收集、汇总与追究责任 有关的资料，并按照制度提出处理方案，逐级上报董事会批准。 第二章 财务报告重大会计差错的认定与处理 第五条 财务报告重大会计差错的认定标准： （一）涉及资产、负债的会计差错金额占最近一个会计年度经审计资产总额的 5%以上； （二）涉及净 ...